<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285920</url>
  </required_header>
  <id_info>
    <org_study_id>821193</org_study_id>
    <nct_id>NCT02285920</nct_id>
  </id_info>
  <brief_title>Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial</brief_title>
  <acronym>SPin-D</acronym>
  <official_title>Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease (ESRD) (SPin-D) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center
      study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to characterize the safety and tolerability of
      multiple doses of chronic SPL therapy compared with placebo in maintenance hemodialysis
      patients and to assess the feasibility of conducting a full-scale, mortality-powered trial of
      SPL. The effects of SPL compared with placebo on multiple cardiovascular efficacy parameters
      will also be analyzed. The primary efficacy parameter will be the change in the E'
      measurement on tissue Doppler echocardiography (TDI) as an index of diastolic function and a
      surrogate for myocardial fibrosis. Secondary cardiac parameters of interest that will be
      studied in the overall population or in sub-studies include heart rate variability,
      circulating markers of fibrosis, and coronary flow reserve (CFR) as an index of microvascular
      function. These parameters are designed to broaden insight into the potential effects of SPL
      on cardiac structure and function in individuals with dialysis-dependent ESRD and to assess
      the feasibility of conducting a full-scale, mortality-powered trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">July 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Number of Participants With Serum Potassium &gt;6.5 mEq/L</measure>
    <time_frame>0 - 40 weeks</time_frame>
    <description>The number of participants who had serum potassium &gt;6.5 mEq/L was assessed by treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Participants With Serious Hypotension</measure>
    <time_frame>0 - 40 weeks</time_frame>
    <description>The number of participants experiencing serious hypotension, defined as hypotension requiring hospitalization or ED visit and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study Drug Tolerability</measure>
    <time_frame>0 - 36 weeks</time_frame>
    <description>Tolerability is defined as number of participants who experienced permanent study drug discontinuation or dose reduction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Change in Mitral Annular E' Velocity</measure>
    <time_frame>Baseline to 36 weeks</time_frame>
    <description>Change in mitral annular E' velocity measured using Tissue Doppler Index (TDI) echocardiography. Efficacy outcomes were considered exploratory with a goal of detecting signals rather than clearly demonstrating efficacy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of Conducting a Full-scale Mortality-powered Trial</measure>
    <time_frame>0 - 40 weeks</time_frame>
    <description>An objective of this study is to assess the feasibility of conducting a full-scale mortality-powered trial. Feasibility assessed based on recruitment, dropout and loss to follow-up rates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Number of Participants With Serious Hyperkalemia</measure>
    <time_frame>0 - 40 weeks</time_frame>
    <description>Number of patients with serious hyperkalemia requiring hospitalization, emergency/unscheduled dialysis or resin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Hyperkalemia Requiring Adjustment in Treatment</measure>
    <time_frame>0 - 40 weeks</time_frame>
    <description>Hyperkalemia requiring adjustment in dialysate potassium concentration, or discontinuation of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Inter- or Intra-dialytic Hypotension</measure>
    <time_frame>0 - 40 weeks</time_frame>
    <description>Inter- or intra-dialytic hypotension defined as:
Inter-dialytic: systolic blood pressure &lt;90 mm Hg or inter-dialytic hypotension requiring adjustment in anti-hypertensive medications or treatment in a hospital or emergency room.
Intra-dialytic: systolic blood pressure &lt;80 mm Hg during ≥3 dialysis sessions per 30-day period or treatment for either hypotension or symptoms of hypotension during ≥3 dialysis sessions per 30-day period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Cardiovascular Death</measure>
    <time_frame>0 - 40 weeks</time_frame>
    <description>Number of Cardiovascular deaths defined as death due to myocardial infarction, congestive heart failure, cardiac valvular disease, arrhythmia, sudden death, stroke, or peripheral arterial disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Secondary Cardiac Outcome Measure - Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Baseline - 36 weeks</time_frame>
    <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function
• Change in left ventricular ejection fraction between Baseline and 36 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Secondary Cardiac Outcome Measures Left Ventricular Mass Index (LVMI)</measure>
    <time_frame>Baseline - 36 weeks</time_frame>
    <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• Change in left ventricular mass index (LVMI) between baseline and 36 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Secondary Cardiac Outcome Measures - Ratio of Mitral Peak Velocity to Diastolic Mitral Annular Velocity (E/E')</measure>
    <time_frame>Baseline - 36 weeks</time_frame>
    <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• E/E' is the ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Secondary Cardiac Outcome Measures - Left Ventricular Global Longitudinal Strain (LVGLS)</measure>
    <time_frame>Baseline - 36 weeks</time_frame>
    <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• Change in myocardial strain and strain rate between baseline and 36 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Combined Incidence of Potassium &gt;6.5 mEq/L or Serious Hyperkalemia</measure>
    <time_frame>0 - 40 Weeks</time_frame>
    <description>The number of participants who had serum potassium &gt;6.5 mEq/L or serious hyperkalemia was assessed by treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Spironolactone 12.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be treated with placebo for 36 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Spironolactone 12.5 mg</arm_group_label>
    <arm_group_label>Spironolactone 25 mg</arm_group_label>
    <arm_group_label>Spironolactone 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Maintenance hemodialysis therapy for end-stage renal disease

          2. Age 18-85 years

          3. ≥3 calendar months since dialysis initiation. Note if a patient has been on dialysis
             for ≥3 but less than 6 calendar months, there must be no hospitalizations during the 6
             weeks prior to screening, and no change in estimated dry weight (EDW) within 2 weeks
             of the screening date.

          4. For women of childbearing potential, willingness to use a highly effective method of
             birth control for up to 4 weeks after the last dose to study drug.

          5. Ability to provide informed consent

        Exclusion Criteria:

          1. Serum potassium ≥6.5 mEq/L within the 3 months prior to screening

          2. Serum potassium level ≥6.0 mEq/L within 2 weeks prior to the baseline visit. If a
             potassium value is not available through routine clinical care during this 2-week
             period a potassium measurement will be performed as a research test.

          3. Unscheduled dialysis for hyperkalemia within the 3 months prior to screening

          4. Pre-dialysis systolic blood pressure &lt;100 mm Hg within 2 weeks prior to screening or
             at the baseline visit

          5. 2 or more dialysis sessions within the month prior to screening with either 2
             intra-dialytic measurements of systolic blood pressure &lt;80 mm Hg or muscle cramping,
             light-headedness, nausea or hypotension requiring infusion of saline or other
             intervention directed at hypotension

          6. Current dual use of angiotensin converting enzyme inhibitor (ACEI) and angiotensin
             receptor blocker (ARB)

          7. Current use of digoxin

          8. Current use of spironolactone or eplerenone

          9. Allergy to spironolactone

         10. Inability to maintain dialysis machine blood flow ≥300 mL/min during any of the most
             recent 3 dialysis sessions prior to the screening visit as an indicator of vascular
             access dysfunction

         11. Mitral valve repair or replacement

         12. Severe mitral valve disease by echocardiography, coronary angiography or cardiac
             magnetic resonance imaging

         13. Anticipated kidney transplant, change to peritoneal dialysis, or transfer to another
             dialysis unit within 9 months

         14. Expected survival &lt;9 months

         15. Pregnancy, anticipated pregnancy, or breastfeeding

         16. Incarceration

         17. Participation in another intervention study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura M Dember, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney Research Institute, University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <results_first_submitted>February 19, 2019</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>spironolactone</keyword>
  <keyword>cardiac fibrosis</keyword>
  <keyword>diastolic function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02285920/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Spironolactone 12.5 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Spironolactone 25 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Spironolactone 50 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Kidney transplantation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change to peritoneal dialysis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to non-participating unit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dialysis discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were enrolled from dialysis units affiliated with four U.S. academic medical centers. The Institutional Review Boards affiliated with the clinical centers and with the data coordinating center approved the protocol and all participants provided informed consent.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Spironolactone 12.5 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Spironolactone 25 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Spironolactone 50 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="11.5"/>
                    <measurement group_id="B2" value="55.1" spread="13.6"/>
                    <measurement group_id="B3" value="53.3" spread="13.5"/>
                    <measurement group_id="B4" value="55.5" spread="9.8"/>
                    <measurement group_id="B5" value="55.5" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety - Number of Participants With Serum Potassium &gt;6.5 mEq/L</title>
        <description>The number of participants who had serum potassium &gt;6.5 mEq/L was assessed by treatment arm.</description>
        <time_frame>0 - 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Number of Participants With Serum Potassium &gt;6.5 mEq/L</title>
          <description>The number of participants who had serum potassium &gt;6.5 mEq/L was assessed by treatment arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety - Participants With Serious Hypotension</title>
        <description>The number of participants experiencing serious hypotension, defined as hypotension requiring hospitalization or ED visit and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection).</description>
        <time_frame>0 - 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Participants With Serious Hypotension</title>
          <description>The number of participants experiencing serious hypotension, defined as hypotension requiring hospitalization or ED visit and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Study Drug Tolerability</title>
        <description>Tolerability is defined as number of participants who experienced permanent study drug discontinuation or dose reduction.</description>
        <time_frame>0 - 36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Tolerability</title>
          <description>Tolerability is defined as number of participants who experienced permanent study drug discontinuation or dose reduction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Change in Mitral Annular E' Velocity</title>
        <description>Change in mitral annular E' velocity measured using Tissue Doppler Index (TDI) echocardiography. Efficacy outcomes were considered exploratory with a goal of detecting signals rather than clearly demonstrating efficacy.</description>
        <time_frame>Baseline to 36 weeks</time_frame>
        <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Change in Mitral Annular E' Velocity</title>
          <description>Change in mitral annular E' velocity measured using Tissue Doppler Index (TDI) echocardiography. Efficacy outcomes were considered exploratory with a goal of detecting signals rather than clearly demonstrating efficacy.</description>
          <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
          <units>cm/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MA E'</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="1.7"/>
                    <measurement group_id="O2" value="7.6" spread="1.8"/>
                    <measurement group_id="O3" value="7.8" spread="1.9"/>
                    <measurement group_id="O4" value="7.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Week MA E'</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="1.9"/>
                    <measurement group_id="O2" value="7.4" spread="1.9"/>
                    <measurement group_id="O3" value="7.7" spread="1.4"/>
                    <measurement group_id="O4" value="7.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline - 36 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.1"/>
                    <measurement group_id="O2" value="-0.2" spread="1.0"/>
                    <measurement group_id="O3" value="-0.1" spread="1.2"/>
                    <measurement group_id="O4" value="0.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of Conducting a Full-scale Mortality-powered Trial</title>
        <description>An objective of this study is to assess the feasibility of conducting a full-scale mortality-powered trial. Feasibility assessed based on recruitment, dropout and loss to follow-up rates.</description>
        <time_frame>0 - 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Conducting a Full-scale Mortality-powered Trial</title>
          <description>An objective of this study is to assess the feasibility of conducting a full-scale mortality-powered trial. Feasibility assessed based on recruitment, dropout and loss to follow-up rates.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Kidney transplantation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change to peritoneal dialysis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transfer to non-participating facility</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dialysis discontinued</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Study completed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Number of Participants With Serious Hyperkalemia</title>
        <description>Number of patients with serious hyperkalemia requiring hospitalization, emergency/unscheduled dialysis or resin therapy</description>
        <time_frame>0 - 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Number of Participants With Serious Hyperkalemia</title>
          <description>Number of patients with serious hyperkalemia requiring hospitalization, emergency/unscheduled dialysis or resin therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Hyperkalemia Requiring Adjustment in Treatment</title>
        <description>Hyperkalemia requiring adjustment in dialysate potassium concentration, or discontinuation of study medication</description>
        <time_frame>0 - 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Hyperkalemia Requiring Adjustment in Treatment</title>
          <description>Hyperkalemia requiring adjustment in dialysate potassium concentration, or discontinuation of study medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Inter- or Intra-dialytic Hypotension</title>
        <description>Inter- or intra-dialytic hypotension defined as:
Inter-dialytic: systolic blood pressure &lt;90 mm Hg or inter-dialytic hypotension requiring adjustment in anti-hypertensive medications or treatment in a hospital or emergency room.
Intra-dialytic: systolic blood pressure &lt;80 mm Hg during ≥3 dialysis sessions per 30-day period or treatment for either hypotension or symptoms of hypotension during ≥3 dialysis sessions per 30-day period</description>
        <time_frame>0 - 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Inter- or Intra-dialytic Hypotension</title>
          <description>Inter- or intra-dialytic hypotension defined as:
Inter-dialytic: systolic blood pressure &lt;90 mm Hg or inter-dialytic hypotension requiring adjustment in anti-hypertensive medications or treatment in a hospital or emergency room.
Intra-dialytic: systolic blood pressure &lt;80 mm Hg during ≥3 dialysis sessions per 30-day period or treatment for either hypotension or symptoms of hypotension during ≥3 dialysis sessions per 30-day period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Inter-dialytic hypotension only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intra-dialytic hypotension only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Inter- &amp; intra-dialytic hypotension</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No inter- or intra-dialytic hypotension</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Cardiovascular Death</title>
        <description>Number of Cardiovascular deaths defined as death due to myocardial infarction, congestive heart failure, cardiac valvular disease, arrhythmia, sudden death, stroke, or peripheral arterial disease</description>
        <time_frame>0 - 40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Cardiovascular Death</title>
          <description>Number of Cardiovascular deaths defined as death due to myocardial infarction, congestive heart failure, cardiac valvular disease, arrhythmia, sudden death, stroke, or peripheral arterial disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy - Secondary Cardiac Outcome Measure - Left Ventricular Ejection Fraction (LVEF)</title>
        <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function
• Change in left ventricular ejection fraction between Baseline and 36 weeks</description>
        <time_frame>Baseline - 36 weeks</time_frame>
        <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Secondary Cardiac Outcome Measure - Left Ventricular Ejection Fraction (LVEF)</title>
          <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function
• Change in left ventricular ejection fraction between Baseline and 36 weeks</description>
          <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
          <units>percent ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEF Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="4.0"/>
                    <measurement group_id="O2" value="65.9" spread="8.5"/>
                    <measurement group_id="O3" value="66.0" spread="11.4"/>
                    <measurement group_id="O4" value="68.2" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEF 36-Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="3.1"/>
                    <measurement group_id="O2" value="66.9" spread="9.9"/>
                    <measurement group_id="O3" value="65.3" spread="13.9"/>
                    <measurement group_id="O4" value="69.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEF Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="4.1"/>
                    <measurement group_id="O2" value="1.0" spread="4.7"/>
                    <measurement group_id="O3" value="-0.7" spread="7.3"/>
                    <measurement group_id="O4" value="1.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy - Secondary Cardiac Outcome Measures Left Ventricular Mass Index (LVMI)</title>
        <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• Change in left ventricular mass index (LVMI) between baseline and 36 weeks</description>
        <time_frame>Baseline - 36 weeks</time_frame>
        <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Secondary Cardiac Outcome Measures Left Ventricular Mass Index (LVMI)</title>
          <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• Change in left ventricular mass index (LVMI) between baseline and 36 weeks</description>
          <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVMI Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.2" spread="25.2"/>
                    <measurement group_id="O2" value="115.5" spread="26.7"/>
                    <measurement group_id="O3" value="116.4" spread="26.9"/>
                    <measurement group_id="O4" value="106.3" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVMI 36-Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" spread="22.4"/>
                    <measurement group_id="O2" value="104.6" spread="27.0"/>
                    <measurement group_id="O3" value="109.1" spread="30.5"/>
                    <measurement group_id="O4" value="96.5" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVMI Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="11.9"/>
                    <measurement group_id="O2" value="-10.9" spread="18.1"/>
                    <measurement group_id="O3" value="-7.3" spread="21.0"/>
                    <measurement group_id="O4" value="-9.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy - Secondary Cardiac Outcome Measures - Ratio of Mitral Peak Velocity to Diastolic Mitral Annular Velocity (E/E')</title>
        <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• E/E' is the ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E')</description>
        <time_frame>Baseline - 36 weeks</time_frame>
        <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Secondary Cardiac Outcome Measures - Ratio of Mitral Peak Velocity to Diastolic Mitral Annular Velocity (E/E')</title>
          <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• E/E' is the ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E')</description>
          <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>E/E' Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="5.8"/>
                    <measurement group_id="O2" value="11.8" spread="6.2"/>
                    <measurement group_id="O3" value="9.2" spread="5.0"/>
                    <measurement group_id="O4" value="12.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E/E' 36-Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="7.0"/>
                    <measurement group_id="O2" value="12.2" spread="80."/>
                    <measurement group_id="O3" value="10.6" spread="3.9"/>
                    <measurement group_id="O4" value="11.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E/E' Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="3.6"/>
                    <measurement group_id="O2" value="0.4" spread="4.4"/>
                    <measurement group_id="O3" value="1.4" spread="2.2"/>
                    <measurement group_id="O4" value="-0.6" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy - Secondary Cardiac Outcome Measures - Left Ventricular Global Longitudinal Strain (LVGLS)</title>
        <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• Change in myocardial strain and strain rate between baseline and 36 weeks</description>
        <time_frame>Baseline - 36 weeks</time_frame>
        <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Secondary Cardiac Outcome Measures - Left Ventricular Global Longitudinal Strain (LVGLS)</title>
          <description>Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,
• Change in myocardial strain and strain rate between baseline and 36 weeks</description>
          <population>The number of participants analyzed reflects those who had analyzable echocardiogram data at both study time points.</population>
          <units>% of myocardial shortening</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVGLS Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="2.8"/>
                    <measurement group_id="O2" value="-16.7" spread="3.3"/>
                    <measurement group_id="O3" value="-17.2" spread="4.2"/>
                    <measurement group_id="O4" value="-17.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVGLS 36-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" spread="2.8"/>
                    <measurement group_id="O2" value="-17.0" spread="3.3"/>
                    <measurement group_id="O3" value="-17.0" spread="3.9"/>
                    <measurement group_id="O4" value="-18.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVGLS Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.3"/>
                    <measurement group_id="O2" value="-0.3" spread="3.3"/>
                    <measurement group_id="O3" value="0.2" spread="2.7"/>
                    <measurement group_id="O4" value="-0.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Combined Incidence of Potassium &gt;6.5 mEq/L or Serious Hyperkalemia</title>
        <description>The number of participants who had serum potassium &gt;6.5 mEq/L or serious hyperkalemia was assessed by treatment arm.</description>
        <time_frame>0 - 40 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Spironolactone 12.5 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone 25 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone 50 mg</title>
            <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Combined Incidence of Potassium &gt;6.5 mEq/L or Serious Hyperkalemia</title>
          <description>The number of participants who had serum potassium &gt;6.5 mEq/L or serious hyperkalemia was assessed by treatment arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed at each study visit during Weeks 1 - 40 of trial participation.</time_frame>
      <desc>Specific signs and symptoms, anticipated in patients treated with spironolactone, were collected on the Adverse Event of Interest form.
Adverse events are reported according to the MedDRA hierarchy. The System Organ Class is comprised of a variety of related High Level Group Terms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants will be treated with placebo for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Spironolactone 12.5 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Spironolactone 25 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Spironolactone 50 mg</title>
          <description>Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
Spironolactone: The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute MI, atrial fibrillation, bradycardia, palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, diarrhea, GI hemorrhage, nausea, vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia, chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemobilia, hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia, influenza, osteomyelitis, pneumonia. sepsis, skin graft infection, UTI, viral infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>AVfistula site hemorrhage, vascular access complications, fall, laceration, rib fracture</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac catheterisation, fistulogram, pleural biopsy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia, hypocalcemia, fluid overload</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="14" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia, back pain, neck pain, extremity pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer, renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder, dementia, headache, paralysis, syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety, depression, mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder mass, hematuria, urinary retention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma, COPD, cough , dyspnea, pleural effusion, stridor</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="13" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister, erythema, pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty, catheter placement, toe amputation, renal transplant, thrombectomy, nephrectomy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension, hypotension, thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="13" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, nausea, diarrhea, constipation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E3" events="21" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, peripheral edema, malaise</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis, diverticulitis, cystitis, cellulitis, naspharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall, rib fracture, vascular graft complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Skin biopsy, liver biopsy, low hemoglobin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia, hyperphosphatemia, hypercalcemia, gout</sub_title>
                <counts group_id="E1" events="70" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E2" events="26" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E3" events="34" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E4" events="39" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia, arthritis, osteoarthritis, tendonitis, neck pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" events="10" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness, headache, migraine, tremor, syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria, hematuria, incontinence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness, enlargement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD, pleural effusion, asthma, cough, dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis, rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>AV fistula, thrombectomy, catheter placement, stent placment, amputation, vascular operation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="90" subjects_affected="25" subjects_at_risk="51"/>
                <counts group_id="E2" events="30" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E3" events="46" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E4" events="75" subjects_affected="17" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura M. Dember, MD</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-573-5264</phone>
      <email>ldember@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

